GlassScriptPhysician profile
David John Jaskierny
NPI 1205913126
$311.90
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.23 · 2021: $32.42 · 2022: $98.88 · 2023: $152 · 2024: $15.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $167.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $89.40 | 2022-2023 | Erleada |
| Dendreon Pharmaceuticals LLC | $46.83 | 2021-2023 | Provenge |
| Urovant Sciences INC | $29.61 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.84 | 2022 | |
| Foundation Medicine, INC. | $23.23 | 2023 | Foundationone Cdx |
| Accord Healthcare, INC. | $21.21 | 2023 | |
| Alnylam Pharmaceuticals INC. | $19.98 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.97 | 2023 | |
| Sumitomo Pharma America, INC. | $15.05 | 2024 | Gemtesa |
| Amgen INC. | $13.23 | 2019 | |
| Urogen Pharma, INC. | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jaskierny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.